[go: up one dir, main page]

UY37854A - Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos - Google Patents

Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos

Info

Publication number
UY37854A
UY37854A UY0001037854A UY37854A UY37854A UY 37854 A UY37854 A UY 37854A UY 0001037854 A UY0001037854 A UY 0001037854A UY 37854 A UY37854 A UY 37854A UY 37854 A UY37854 A UY 37854A
Authority
UY
Uruguay
Prior art keywords
piperidina
diona
oxoisoindolin
derivatives
same
Prior art date
Application number
UY0001037854A
Other languages
English (en)
Inventor
Scott Visser Michael
Simone Bonazzi
Artiom Cernijenko
Aleem Fazal
Eric John Beckwith Rohan
Bhanudasji Tichkule Ritesh
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY37854A publication Critical patent/UY37854A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)

Abstract

La presente invención proporciona un compuesto de fórmula (I'): O una sal, hidrato, solvato, profármaco, estereoisómero o tautómero farmacéuticamente aceptable del mismo, en donde R1, R2, Rx, X1, n, n1, y q son como se definen en el presente documento, así como métodos para fabricarlos y usarlos.
UY0001037854A 2017-08-23 2018-08-22 Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos UY37854A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762549225P 2017-08-23 2017-08-23

Publications (1)

Publication Number Publication Date
UY37854A true UY37854A (es) 2019-03-29

Family

ID=63638171

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037854A UY37854A (es) 2017-08-23 2018-08-22 Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos

Country Status (38)

Country Link
US (5) US10414755B2 (es)
EP (2) EP4183782A1 (es)
JP (1) JP7386787B2 (es)
KR (1) KR20200044038A (es)
CN (1) CN111051298B (es)
AR (1) AR112529A1 (es)
AU (3) AU2018319577B2 (es)
BR (1) BR112020003373B1 (es)
CA (1) CA3072694A1 (es)
CL (1) CL2020000427A1 (es)
CO (1) CO2020001860A2 (es)
CR (1) CR20200081A (es)
CU (1) CU20200014A7 (es)
DK (1) DK3672949T5 (es)
DO (1) DOP2020000037A (es)
EA (1) EA202090553A1 (es)
EC (1) ECSP20013248A (es)
ES (1) ES2940448T3 (es)
FI (1) FI3672949T3 (es)
HR (1) HRP20230244T1 (es)
HU (1) HUE061895T2 (es)
IL (1) IL272748B2 (es)
JO (1) JOP20200042A1 (es)
LT (1) LT3672949T (es)
MA (1) MA49952B1 (es)
MX (1) MX2020002060A (es)
PE (1) PE20200796A1 (es)
PH (1) PH12020500125A1 (es)
PL (1) PL3672949T3 (es)
PT (1) PT3672949T (es)
RS (1) RS64058B9 (es)
SA (1) SA520411325B1 (es)
SG (1) SG11202000490PA (es)
SI (1) SI3672949T1 (es)
TW (1) TWI793151B (es)
UY (1) UY37854A (es)
WO (1) WO2019038717A1 (es)
ZA (1) ZA202000208B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
CN109562107A (zh) * 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
CA3095912A1 (en) * 2018-04-13 2019-10-17 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
IL278951B (en) * 2018-07-10 2022-08-01 Novartis Ag History of 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-6,2-dione and their use in the treatment of ikzf2-dependent diseases
AR116109A1 (es) * 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
AU2019391016B2 (en) 2018-12-03 2025-05-29 Dana-Farber Cancer Institute, Inc. Small molecule degraders of helios and methods of use
EP3897637A1 (en) * 2018-12-20 2021-10-27 Novartis AG Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
MX2021009763A (es) * 2019-02-15 2021-09-08 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
KR20210129672A (ko) * 2019-02-15 2021-10-28 노파르티스 아게 치환된 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도
BR112021019669A2 (pt) 2019-04-12 2021-12-07 C4 Therapeutics Inc Composto, composição farmacêutica, método para tratar um transtorno, composto para uso na produção de um medicamento, e, uso de um composto no tratamento de um transtorno
EP3959320A1 (en) 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
CN114502540A (zh) 2019-05-31 2022-05-13 医肯纳肿瘤学公司 Tead抑制剂和其用途
BR112021024108A2 (pt) 2019-05-31 2022-03-22 Ikena Oncology Inc Inibidores de tead e usos dos mesmos
CA3154942A1 (en) * 2019-10-30 2021-05-06 Nathanael S. Gray Small molecule degraders of helios and methods of use
CN110862395B (zh) * 2019-11-13 2020-09-29 株洲千金药业股份有限公司 一种制备他达拉非重要杂质的原料化合物的制备方法
IL293027A (en) * 2019-11-19 2022-07-01 Bristol Myers Squibb Co Compounds useful as inhibitors of Helios protein
TW202140441A (zh) * 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
EP4144728A4 (en) * 2020-04-30 2023-08-23 Shanghaitech University HETEROCYCLIC COMPOUND BASED ON A GLUTARIMIDE SKELETON AND USES THEREOF
IL298262A (en) 2020-06-23 2023-01-01 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
TW202216684A (zh) * 2020-07-09 2022-05-01 大陸商四川海思科製藥有限公司 用於抑制與降解雄激素受體的化合物、醫藥組合物及其應用
JP2023536164A (ja) * 2020-08-03 2023-08-23 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
EP4188373A1 (en) * 2020-08-03 2023-06-07 Captor Therapeutics S.A. Low molecular weight protein degraders and their applications
PE20230847A1 (es) 2020-09-23 2023-05-23 St Jude Childrens Res Hospital Inc Analogos de n-(2-(2,6-dioxopiperidin-3-il)-1,3-dioxoisoindolin-5-il)arilsufonamida sustituidos como modulares de la proteina cereblon
JP2023545274A (ja) * 2020-10-07 2023-10-27 クルゲン（シャンハイ），インク． 癌を処置する化合物および方法
IL302038A (en) * 2020-10-14 2023-06-01 C4 Therapeutics Inc Tricyclic ligands for degradation of ikzf2 or ikzf4
KR20230090318A (ko) * 2020-10-16 2023-06-21 다나-파버 캔서 인스티튜트 인크. 헬리오스의 피페리디닐 소분자 분해 및 사용 방법들
CN116669769A (zh) * 2020-10-16 2023-08-29 达纳－法伯癌症研究所公司 Helios的哌啶基小分子降解剂和使用方法
WO2022120355A1 (en) * 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead degraders and uses thereof
UY39671A (es) * 2021-03-15 2022-10-31 Novartis Ag Derivados de pirazolopiridina y sus usos.
MX2023011715A (es) 2021-04-06 2023-10-12 Bristol Myers Squibb Co Compuestos de oxoisoindolina sustituidos con piridinilo.
US20240217970A1 (en) * 2021-04-29 2024-07-04 Dana-Farber Cancer Institute, Inc. Phthalimido cereblon complex binders and transcription factor degraders and methods of use
CA3215907A1 (en) * 2021-04-29 2022-11-03 Whitney L. PETRILLI Substituted 2-(2,6-dioxopiperidin-3-yl)-5-(1-piperidin-4-yl)isoindoline-1,3-dione derivatives and uses thereof
WO2023283425A1 (en) 2021-07-09 2023-01-12 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2
CA3223636A1 (en) 2021-08-06 2023-02-09 Christopher Walton CARROLL Compositions and methods for selective degradation of engineered proteins
TW202321219A (zh) * 2021-08-11 2023-06-01 大陸商四川海思科製藥有限公司 雜環衍生物及其組合物和藥學上的應用
JP2024539252A (ja) 2021-10-28 2024-10-28 ギリアード サイエンシーズ， インコーポレイテッド ピリジジン－３（２ｈ）－オン誘導体
AU2022376954A1 (en) 2021-10-29 2024-05-02 Gilead Sciences, Inc. Cd73 compounds
CA3239528A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CA3237577A1 (en) * 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
CN116640122A (zh) * 2022-02-16 2023-08-25 苏州国匡医药科技有限公司 Ikzf2降解剂及包含其的药物组合物和用途
AU2023233730A1 (en) 2022-03-17 2024-09-26 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
KR20250024899A (ko) * 2022-03-25 2025-02-20 온코피아 테라퓨틱스, 인코퍼레이티드. 디/비/에이/ 에스케이 라이프 사이언스 랩스 Ikzf2 분해제로서의 바이사이클릭 헤테로아릴 함유 화합물
JP2025512805A (ja) * 2022-03-25 2025-04-22 リージェンツ オブ ザ ユニバーシティー オブ ミシガン Ｉｋｚｆ２分解剤及びその使用
WO2023201012A1 (en) * 2022-04-15 2023-10-19 Regents Of The University Of Michigan Ikzf2 degraders and uses thereof
JP2025513258A (ja) 2022-04-21 2025-04-24 ギリアード サイエンシーズ， インコーポレイテッド Ｋｒａ ｇ１２ｄ調節化合物
EP4547657A1 (en) 2022-07-01 2025-05-07 Gilead Sciences, Inc. Cd73 compounds
AU2023320900A1 (en) * 2022-08-10 2025-02-13 Gluetacs Therapeutics (Shanghai) Co., Ltd. Compound based on isoindoline-substituted glutarimide backbone and use thereof
WO2024059107A1 (en) * 2022-09-14 2024-03-21 President And Fellows Of Harvard College Ikzf2 and ck1-alpha degrading compounds and uses thereof
CN120322222A (zh) * 2022-12-07 2025-07-15 杭州格博生物医药有限公司 一种固体分散体、其制备方法和应用
AU2023409398A1 (en) 2022-12-22 2025-06-05 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024162746A1 (ko) * 2023-01-31 2024-08-08 한국화학연구원 Ikzf2를 분해하는 인돌 화합물 및 이의 용도
US20240383922A1 (en) 2023-04-11 2024-11-21 Gilead Sciences, Inc. KRAS Modulating Compounds
AU2024259556A1 (en) 2023-04-21 2025-10-23 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025006720A1 (en) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Kras modulating compounds
TW202519517A (zh) 2023-07-26 2025-05-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2025024663A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025067466A1 (zh) * 2023-09-28 2025-04-03 杭州多域生物技术有限公司 一种杂环化合物、其组合物及应用
WO2025076284A1 (en) * 2023-10-06 2025-04-10 Delphia Therapeutics, Inc. Compounds, pharmaceutical compositions thereof, and methods of using the same
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025113643A1 (en) 2023-12-01 2025-06-05 Gilead Sciences Inc. Anti-fap-light fusion protein and use thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025245178A1 (en) * 2024-05-21 2025-11-27 Innovo Therapeutics, Inc. Pak4, cstf2, or cstf2t protein degraders, pharmaceutical compositions, and therapeutic applications

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114946A (en) 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
US4818541A (en) 1987-08-19 1989-04-04 Schering Corporation Transdermal delivery of enantiomers of phenylpropanolamine
US7196170B2 (en) 1992-09-14 2007-03-27 The General Hospital Corporation Aiolos, Helios, Daedalos and Ikaros: genes, polypeptides, regulatory elements and uses thereof
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
SK9199A3 (en) 1996-07-24 1999-07-12 Celgene Corp 2,6-dioxopiperidines, pharmaceutical composition them containing and their use
AU2001291195A1 (en) 2000-12-01 2002-06-11 Parker Hughes Institute Nucleotide and protein sequence of helios 3 and methods of use
EP1396493A4 (en) 2001-04-26 2005-08-03 Ajinomoto Kk HETEROCYCLIC COMPOUNDS
EP1423115B9 (en) 2001-08-06 2009-09-02 The Children's Medical Center Corporation Antiangiogenic activity of nitrogen substituted thalidomide analogs
US20050203142A1 (en) 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040087558A1 (en) 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US7612096B2 (en) 2003-10-23 2009-11-03 Celgene Corporation Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
US20070161696A1 (en) 2004-04-23 2007-07-12 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
CN101080400A (zh) * 2004-09-03 2007-11-28 细胞基因公司 制备取代的2－(2,6－二氧代哌啶－3－基)－1－氧代异吲哚啉的方法
JP4731867B2 (ja) 2004-10-01 2011-07-27 国立大学法人三重大学 Ｃｄ８陽性の細胞傷害性ｔリンパ球の誘導方法
ZA200704964B (en) 2004-12-01 2008-10-29 Celgene Corp Methods and compositions using immunomodulatory compounds for the treatment of immunodeficiency disorders
DE602005023646D1 (de) 2004-12-10 2010-10-28 Siemens Healthcare Diagnostics Für die vorhersage des ansprechens maligner neoplasie auf eine auf taxan beruhende medizinische behandlung geeignete genetische veränderung
WO2007067500A2 (en) 2005-12-05 2007-06-14 Genomic Health, Inc. Predictors of patient response to treatment with egfr inhibitors
EP1974013A2 (en) 2005-12-29 2008-10-01 Anthrogenesis Corporation Improved composition for collecting and preserving placental stem cells and methods of using the composition
KR20090007347A (ko) 2006-03-22 2009-01-16 버텍스 파마슈티칼스 인코포레이티드 증식성 장애의 치료를 위한 ｃ-ＭＥＴ 단백질 키나제 억제제
US20070269827A1 (en) 2006-05-18 2007-11-22 Oklahoma Medical Research Foundation Predicting and Diagnosing Patients With Autoimmune Disease
KR101342035B1 (ko) 2006-06-20 2013-12-16 한국과학기술연구원 신장독성 및 부작용 유발 약물 검색용 바이오마커 및 이를이용한 신장독성 및 부작용 유발 약물 검색 방법
US8877780B2 (en) * 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
JP2009092508A (ja) 2007-10-09 2009-04-30 Norihiro Nishimoto リウマチ治療剤の効果の予測方法
US20100247580A1 (en) 2007-11-30 2010-09-30 Thierry Coche Method for Classifying Cancer Patients as Responder or Non-Responder to Immunotherapy
KR100957051B1 (ko) 2007-12-28 2010-05-13 한국과학기술연구원 니트로푸란토인 처리에 따른, 폐독성 유발 약물 검색용마커유전자 및 이를 이용한 검색 방법
GB2456390A (en) 2008-01-15 2009-07-22 Glaxo Group Ltd Bipolar disorder treatments
WO2009094592A2 (en) 2008-01-23 2009-07-30 Perlegen Sciences, Inc. Genetic basis of alzheimer's disease and diagnosis and treatment thereof
CA2718887A1 (en) 2008-03-19 2009-09-24 Existence Genetics Llc Genetic analysis
US20110229498A1 (en) 2008-05-08 2011-09-22 The Johns Hopkins University Compositions and methods for modulating an immune response
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
US9212177B2 (en) 2009-08-05 2015-12-15 Versitech Limited Antiviral compounds and methods of making and using thereof
EP2462138B1 (en) 2009-08-05 2014-09-24 Versitech Limited Antiviral compounds and methods of making
JP2013507989A (ja) 2009-10-26 2013-03-07 アボット・ラボラトリーズ 非小細胞肺癌の予後に関連する染色体異常の検出
AU2011253481A1 (en) 2010-05-12 2013-01-10 Steven E. Schutzer Diagnostic markers for neuropsychiatric disease
US20120142701A1 (en) 2010-05-28 2012-06-07 The University Of Hong Kong Compounds and methods for the treatment of proliferative diseases
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
US20130281304A1 (en) 2010-08-13 2013-10-24 Andrew P. Feinberg Comprehensive Methylome Map of Myeloid and Lymphoid Commitment from Hematopoietic Proenitors
EP2630158B1 (en) 2010-10-22 2018-12-12 Dana-Farber Cancer Institute, Inc. Discovery of regulatory t cells programmed to suppress an immune response
EP3520793B1 (en) 2011-06-06 2023-03-29 University of Iowa Research Foundation Substances and compostions for use in methods of inhibiting muscle atrophy
WO2012175613A1 (en) 2011-06-21 2012-12-27 Innate Pharma NKp46-MEDIATED NK CELL TUNING
JP6173310B2 (ja) 2011-07-01 2017-08-02 ベックマン コールター， インコーポレイテッド 調節性ｔ細胞ならびにそれを同定する方法、それを取得する方法およびそれを使用して免疫ベースの障害を処置する方法
CN103797120B (zh) 2011-09-16 2017-04-12 上海长海医院 前列腺癌的生物学标志物、治疗靶点及其用途
US10238694B2 (en) 2011-12-01 2019-03-26 The University Of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory T cells
US9481866B2 (en) 2011-12-16 2016-11-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T cell populations enriched for stable regulatory T-cells
WO2013098797A2 (en) 2011-12-31 2013-07-04 Kuriakose Moni Abraham Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer
WO2013131045A1 (en) 2012-03-02 2013-09-06 The Regents Of The University Of California Expansion of alloantigen-reactive regulatory t cells
GB201207297D0 (en) 2012-04-26 2012-06-06 Senzagen Ab Analytical methods and arrays for use in the same
GB201213571D0 (en) 2012-07-31 2012-09-12 Univ Leuven Kath Growth factor cocktail to enhnce osteogenic differentiayion of mesenchymal
EP2682750A1 (en) 2012-07-02 2014-01-08 Sotio a.s. In vitro method for the diagnosis and surveillance of cancer
EP2903692B1 (en) 2012-10-08 2019-12-25 St. Jude Children's Research Hospital Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
EP2953524B1 (en) 2013-02-06 2018-08-01 Freenome Holdings Inc. Systems and methods for early disease detection and real-time disease monitoring
WO2014153069A2 (en) 2013-03-14 2014-09-25 Children's Medical Center Corporation Compositions and methods for reprogramming hematopoietic stem cell lineages
SG11201506723XA (en) 2013-03-15 2015-09-29 Veracyte Inc Methods and compositions for classification of samples
US20160122821A1 (en) 2013-06-10 2016-05-05 Suregene, Llc Genetic markers of antipsychotic response
CA2923700A1 (en) 2013-09-09 2015-03-12 The Scripps Research Institute Methods and systems for analysis of organ transplantation
WO2015050875A1 (en) 2013-10-01 2015-04-09 The Regents Of The University Of California Endometriosis classifier
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
WO2015107196A1 (en) 2014-01-20 2015-07-23 Institut Curie Use of thalidomide or analogs thereof for preventing neurologic disorders induced by brain irradiation
KR102320082B1 (ko) * 2014-04-14 2021-10-29 아비나스 오퍼레이션스, 인코포레이티드 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
US20160058872A1 (en) * 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
JP6905934B2 (ja) 2014-12-05 2021-07-21 ファウンデーション・メディシン・インコーポレイテッド 腫瘍試料の多重遺伝子分析
EP3034620A1 (en) 2014-12-17 2016-06-22 Diaxonhit Compositions and methods for diagnosing thyroid cancer
WO2016103269A1 (en) 2014-12-23 2016-06-30 Ramot At Tel-Aviv University Ltd. Populations of neural progenitor cells and methods of producing and using same
CA2973873A1 (en) 2015-01-20 2016-07-28 Merial, Inc. Anthelmintic compounds, compositions and method of using thereof
EP3050570A1 (en) 2015-01-31 2016-08-03 Neurovision Pharma GmbH Pharmaceutical composition consisting of a combination of G-CSF with GM-CSF
WO2016140974A1 (en) 2015-03-01 2016-09-09 Novena Therapeutics Inc. Process for measuring tumor response to an initial oncology treatment
CA2986141C (en) 2015-05-22 2020-07-28 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
JP6585737B2 (ja) 2015-06-02 2019-10-02 セルジーン コーポレイション セレブロン関連タンパク質の比を使用してがんの治療のための薬物の有効性を決定するための方法
EP3302548A4 (en) 2015-06-03 2019-01-02 Dana Farber Cancer Institute, Inc. Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy
JP2018519295A (ja) 2015-06-22 2018-07-19 プレジデント アンド フェローズ オブ ハーバード カレッジ 粘膜固有層調節性ｔ細胞の誘導
WO2017042337A1 (en) 2015-09-09 2017-03-16 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmhotz-Gemeinschaft Short-chain fatty acids for use in the treatment of cardiovascular disease
US20180250369A1 (en) 2015-09-11 2018-09-06 Ventria Bioscience, Inc. Lactoferrin compositions and methods for modulation of t cell subtypes and treatment of autoimmune diseases
US10954300B2 (en) 2015-09-28 2021-03-23 The Trustees Of Columbia University In The City Of New York Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
KR102838444B1 (ko) 2015-09-30 2025-07-24 더 유니버시티 코트 오브 더 유니버시티 오브 애버딘 탈리도마이드 유사체 및 사용 방법
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
US11090373B2 (en) 2015-12-04 2021-08-17 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Antigen-specific T cells for inducing immune tolerance
EP3429603B1 (en) 2016-03-15 2021-12-29 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
JP7001614B2 (ja) 2016-04-06 2022-02-03 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン リガンド依存性の標的タンパク質分解のための単官能性中間体
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
US10584101B2 (en) 2016-10-11 2020-03-10 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
EP3558994A4 (en) 2016-12-23 2021-05-12 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FAST ACCELERATED FIBROSARCOMA POLYPEPTIDES
EP3559006A4 (en) 2016-12-23 2021-03-03 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF F TAL LIVER KINASE POLYPEPTIDES
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
CA3049912A1 (en) 2017-01-26 2018-08-02 Arvinas Operations, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
CN106932576A (zh) 2017-03-22 2017-07-07 山东大学深圳研究院 一种人调节性t细胞的免疫抑制功能的检测方法
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途

Also Published As

Publication number Publication date
CA3072694A1 (en) 2019-02-28
DOP2020000037A (es) 2020-08-15
ECSP20013248A (es) 2020-05-29
AR112529A1 (es) 2019-11-06
PE20200796A1 (es) 2020-08-10
US10647701B2 (en) 2020-05-12
EA202090553A1 (ru) 2020-06-08
JP2020531498A (ja) 2020-11-05
SA520411325B1 (ar) 2022-06-13
PT3672949T (pt) 2023-03-16
CU20200014A7 (es) 2020-11-30
DK3672949T5 (da) 2023-05-01
AU2018319577A1 (en) 2020-02-06
SI3672949T1 (sl) 2023-04-28
IL272748B2 (en) 2023-02-01
WO2019038717A1 (en) 2019-02-28
AU2020277231A1 (en) 2020-12-24
JP7386787B2 (ja) 2023-11-27
HUE061895T2 (hu) 2023-08-28
AU2022231670A1 (en) 2022-10-06
LT3672949T (lt) 2023-04-11
JOP20200042A1 (ar) 2020-02-20
DK3672949T3 (da) 2023-03-27
IL272748A (en) 2020-04-30
ES2940448T3 (es) 2023-05-08
US20190062309A1 (en) 2019-02-28
EP3672949A1 (en) 2020-07-01
TWI793151B (zh) 2023-02-21
CO2020001860A2 (es) 2020-05-29
FI3672949T3 (fi) 2023-03-23
US20210309638A1 (en) 2021-10-07
EP3672949B1 (en) 2022-12-21
EP4183782A1 (en) 2023-05-24
CN111051298B (zh) 2023-06-27
US10414755B2 (en) 2019-09-17
US10640489B2 (en) 2020-05-05
BR112020003373A2 (pt) 2020-08-25
PH12020500125A1 (en) 2020-09-14
IL272748B (en) 2022-10-01
AU2018319577B2 (en) 2020-10-15
MA49952B1 (fr) 2023-03-31
ZA202000208B (en) 2021-07-28
RU2020111556A (ru) 2021-09-23
HRP20230244T1 (hr) 2023-04-14
SG11202000490PA (en) 2020-03-30
RS64058B9 (sr) 2023-08-31
US11053218B2 (en) 2021-07-06
RS64058B1 (sr) 2023-04-28
MX2020002060A (es) 2020-07-13
CN111051298A (zh) 2020-04-21
US20190359594A1 (en) 2019-11-28
EP3672949B9 (en) 2023-04-05
PL3672949T3 (pl) 2023-05-08
MA49952A (fr) 2021-04-28
BR112020003373B1 (pt) 2022-08-09
TW201920143A (zh) 2019-06-01
CL2020000427A1 (es) 2020-08-28
RU2020111556A3 (es) 2021-12-17
US20190367483A1 (en) 2019-12-05
US20200231569A1 (en) 2020-07-23
CR20200081A (es) 2020-05-14
KR20200044038A (ko) 2020-04-28

Similar Documents

Publication Publication Date Title
UY37854A (es) Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos
CY1123994T1 (el) Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4
CL2020001547A1 (es) Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa.
CL2019001714A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer.
MX375323B (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos.
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
UY37927A (es) Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo
EA201791304A1 (ru) Производные изохинолина для лечения вич
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
CU24605B1 (es) Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
MX2018000280A (es) Oxiesteroles y metodos de uso de los mismos.
MX388321B (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
ECSP18003372A (es) Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
MX2021011118A (es) Derivados de azolopiridina macrocíclicos como moduladores de eed y prc2.
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
CY1125082T1 (el) Υποκατεστημενα τριαζολια και μεθοδοι που σχετιζονται με αυτα
CU20170007A7 (es) Compuestos de imidazopiridazina
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CO2020010306A2 (es) Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado.
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
CO2019001644A2 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
SV2016005310A (es) Derivados de diheterociclo enlazado a cicloalquilo

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20231110